ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Levomilnacipran

Also written as “Levomilnacipran ER”, “F2695” and “Levomilnacipran Hydrochloride Extended-Release Capsules”.

Its studies are mostly in Depressive Disorder, Major · Depression · Ischemic Stroke, led by 3 companies.

Drug pageLevomilnacipran: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 7, 201413 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie100 open or runningphase 4since Nov 7, 2014Aug 31, 2009none ahead
Pierre Fabreits history only20 open or runningphase 3since Jul 10, 2012Jul 10, 2012none ahead
Zhejiang Huahai Pharmaceuticalits history only10 open or runningphase 3since Nov 18, 2025Nov 18, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2009First studies: 2 phase 3 studies in Depressive Disorder, MajorFirst studyNCT00969709, NCT00969150
  2. Dec 16, 20092 phase 3 studies in Depressive Disorder, MajorNCT01034462, NCT01034267
  3. Mar 10, 2010Phase 3 study in DepressionNCT01085812 · 734 enrolled · United States, Canada
  4. Dec 3, 2010Phase 2 study in Depressive Disorder, MajorNCT01254305 · 262 enrolled · United States
  5. Jun 10, 2011Phase 3 study in Depressive Disorder, MajorNCT01377194 · 568 enrolled · United States, Canada
  6. Nov 7, 2014Phase 4 study in Depressive Disorder, MajorNCT02288325 · 644 enrolled · United States
  7. Apr 28, 2015Phase 3 study in Depressive Disorder, MajorNCT02431806 · 552 enrolled · United States, Puerto Rico
  8. Jun 15, 2018Phase 3 study in Depressive Disorder, MajorNCT03569475 · 501 enrolled · United States

TargetBeta

“Serotonin transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule

Studies

All 10 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03569475Depressive Disorder, Major · United States3CompletedMar 1, 2021501
NCT02431806Depressive Disorder, Major · United States, Puerto Rico3CompletedAug 19, 2019552
NCT02288325Depressive Disorder, Major · United States4CompletedSep 16, 2016644
NCT01377194Depressive Disorder, Major · United States, Canada3CompletedMar 2012568
NCT01254305Depressive Disorder, Major · United States2CompletedJul 2012262
NCT01085812Depression · United States, Canada3CompletedOct 2011734
NCT01034462Depressive Disorder, Major · United States3CompletedDec 2011442
NCT01034267Depressive Disorder, Major · United States3CompletedJun 2012828
NCT00969709Depressive Disorder, Major · United States3CompletedMay 2011724
NCT00969150Depressive Disorder, Major · United States3CompletedNov 2010362

How it is read

Names in the registry

  • “Levomilnacipran ER”, 11 entries
  • “F2695”, 2 entries
  • “Levomilnacipran Hydrochloride Extended-Release Capsules”, 1 entry
  • “Levomilnacipran”, 1 entry
  • “F2695 SR”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.